|D053120||Respiratory Aspiration NIH||0.50|
|D012120||Respiration Disorders NIH||0.38|
|D012140||Respiratory Tract Diseases NIH||0.32|
|D011024||Pneumonia, Viral NIH||0.14|
|D045169||Severe Acute Respiratory Syndrome NIH||0.06|
|D018352||Coronavirus Infections NIH||0.05|
There is one clinical trial.
The purpose of this open label, randomized, study is to obtain information on the safety and efficacy of 80 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.
Description: Time to deterioration measured by need for NIV, HFNC or intubation need for high flow nasal cannula (HFNC) or need for intubationMeasure: Time to deterioration Time: 14 Days
Description: Time to non-invasive ventilationMeasure: Time to non-invasive ventilation Time: 14 Days
Description: Time to HFNCMeasure: Time to HFNC Time: 14 Days
Description: Time to intubationMeasure: Time to intubation Time: 14 days
Description: Time to patient having stable oxygen saturation (SpO2) greater than 92%Measure: Time to patient having stable oxygen saturation (SpO2) greater than 92% Time: 14 days
Description: Need for supplemental oxygenMeasure: Need for supplemental oxygen Time: 14 days
Description: Change in viral loadMeasure: Change in viral load Time: 30 days
Description: Duration of the Hospital Length of Stay (LOS)Measure: Duration of the Hospital Length of Stay (LOS) Time: 14 days